Trial to Assess Chelation Therapy (TACT) – The TACT Trial

Posted by Dr Dan Carter

The Trial to Assess Chelation Therapy (TACT) was published in the Journal of the American Medical Association (JAMA) on March 27, 2013. The objective was to determine if an EDTA-based chelation treatment reduces cardiovascular events. The trail was a double-blind, placebo-controlled, 2 × 2 factorial randomized design, enrolling 1708 patients aged 50 years or older who had experienced a myocardial infarction (MI) at least 6 weeks prior and had serum creatinine levels of 2.0 mg/dL or less. Participants were recruited in the US and Canada. Enrollment commenced in September 2003 and follow-up continued until October 2011 (median, 55 months). Two hundred eighty nine patients (17% of total; 115 in the EDTA group and 174 in the placebo group) withdrew consent during the trial.

A synopsis of the JAMA abstract:

Patients were randomized to receive 40 infusions of 500 mL chelation solution (3 g disodium EDTA, 7 g ascorbate, B vitamins, electrolytes, procaine, and heparin) (n=839) vs. placebo (n=869) and an oral vitamin-mineral regimen vs. an oral placebo. Weekly infusions were administered for 30 weeks, followed by 10 infusions 2-8 weeks apart. Sixteen percent discontinued infusions (n=38 [16%] in the chelation group and n=41 [15%] in the placebo group) due to adverse events.

The pre-defined primary end point was a composite of total mortality, recurrent MI, stroke, coronary revascularization, or hospitalization for angina. This report describes the treatment comparison of EDTA chelation vs. placebo. The significance threshold required for final analysis was P = .036.

Qualifying previous MIs occurred a median of 4.6 years prior to enrollment. Median age was 65 years, 18% female, 9% nonwhite, and 31% diabetic. The primary end point occurred in 222 (26%) of the chelation group and 261 (30%) of the placebo group (hazard ratio [HR], 0.82 [95% CI, 0.69-0.99]; P = .035). There was no effect on total mortality (chelation: 87 deaths [10%]; placebo, 93 deaths [11%]; HR, 0.93 [95% CI, 0.70-1.25]; P = .64). The effect of EDTA chelation on the components of the primary end point other than death was of similar magnitude as its overall effect (MI: chelation, 6%; placebo, 8%; HR, 0.77 [95% CI, 0.54-1.11]; stroke: chelation, 1.2%; placebo, 1.5%; HR, 0.77 [95% CI, 0.34-1.76]; coronary revascularization: chelation, 15%; placebo, 18%; HR, 0.81 [95% CI, 0.64-1.02]; hospitalization for angina: chelation, 1.6%; placebo, 2.1%; HR, 0.72 [95% CI, 0.35-1.47]). Sensitivity analyses examining the effect of patient dropout and treatment adherence did not alter the results.

Among stable patients with a history of MI, use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes, many of which were revascularization procedures. These results provide evidence to guide further research but are not sufficient to support the routine use of chelation therapy for treatment of patients who have had an MI.

End synopsis

The Mayo Clinic website gave better detail of the infusion solutions:

“For the TACT study, the protocol specified 40 infusions of at least three hours each — 30 weekly infusions followed by 10 maintenance infusions two to eight weeks apart. For the active chelation arm, a 10-component chelation solution was selected to match most closely the standard solution used by chelation practitioners. The solution contained up to 3 g of disodium EDTA, 7 g of ascorbic acid, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2,500 U of unfractionated heparin, 2 mEq of potassium chloride, 840 mg of sodium bicarbonate, 250 mg of pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, 100 mg of procaine, and sterile water to make up 500 mL of solution. The placebo solution consisted of 500 mL of normal saline and 1.2 percent dextrose.”

The following is a summary from and gives an easier visualization of the benefits of EDTA chelation therapy.

  • Composite endpoints: 18% reduction EDTA vs. placebo (p=0.035)
  • Subgroups
  • Diabetes: 39% reduction in composite endpoints vs. placebo (p=0.002)
  • Non-diabetics: 0.04 % reduction vs. placebo (p=0.725)
  • Anterior MI: 37% reduction vs. placebo (p=0.03)

The trial results were discussed extensively at the 2012 American Heart Association (AHA) annual meeting in Los Angeles, where the TACT results were presented. The usual answer in randomized placebo-controlled clinical trials — that the active treatment (chelation) is better than placebo — was not believed by most in attendance to be the cause. Three possible reasons were offered, including:

1. Difference in low-density lipoprotein cholesterol levels at baseline. Subjects randomly assigned to active chelation therapy had a lower baseline LDL than the placebo group (87 mg/dL vs. 90 mg/dL). This level of difference would be expected to result in 3 percent less major cardiovascular events after five years, very close to the 3.5 percent actually seen in the study.

  • Comment Dr Carter – Cholesterol Treatment Trialists (CTT) meta-analysis in 2005, which reported the results for more than 90,000 subjects treated with statins in primary and secondary prevention trials. It found that for every 1 mmol/L (39 mg/dL) reduction in LDL-C, there was a 21% relative reduction in risk for major vascular events. This paper implies that the relationship between LDL-C and CV events is not linear, and in fact a 3 mg LDL-C decrease would lead to 1.6% less risk. This paper later suggests that there is a Log-linear relationship between LDL-C levels and relative risk for CHD.

Ref: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists’ (CTT) Collaborators. Lancet. 2005 Oct 8; 366(9493):1267-78. PMID: 16214597

2. Placebo glucose infusion in the diabetic group. Since most of the benefit of chelation was seen in diabetic patients, some postulated that the placebo glucose infusion may have led to increased adverse outcomes in this subset.

  • Comment Dr Carter – It would be very difficult to design a trial using different placebos for different subgroups; analysis would be too confounded. The placebo infusion used in the TACT trial contained 1.2% dextrose (glucose) in 500 mL solution, this amounts to 6000 mg or 6 grams dextrose once a week, administered over 3 hours, during the most active portion of the trial. To put this in context, a 12 ounce Coca Cola contains 39 grams of sugar (19.5 grams each of dextrose and fructose), 8 ounces Minute Maid orange juice contains 21 grams sugar (mainly fructose), one slice white bread contains 50 grams carbohydrate (blood sugar spike will not be as rapid as glucose, but amount of carbohydrate is significant). It would seem that 6 grams glucose consumed over 3 hours would not spike blood glucose significantly.
  • This from, Nutrition Recommendations and Interventions for Diabetes: A position statement of the American Diabetes Association, illustrates the point that 6 grams carbohydrate once a week is not significant; they are searching for implausible reasons!

    Low-carbohydrate diets, restricting total carbohydrate to <130 g/day, are not recommended in the management of diabetes.

3. Incomplete data due to dropout. Seventeen percent of patients withdrew consent (3 percent-5 percent is common in large trials), which prohibited investigators from ascertaining any endpoint data, thereby potentially missing some major cardiovascular events.

  • Comment Dr Carter – The TACT trial demanded major time commitments from enrollees. Travel time, administration of the infusion (3 hours plus time to start and disconnect IV, perform vital sign exams), and blood test collections. The majority of drug trials involve administration of an oral drug; something that can be done at the patient’s home or work, so it is not too surprising that 17% withdrew from the trial.

The AHA appears to be applying weak arguments to contest the significance of the outcomes.

Next post: A talk by the TACT Trial principle investigator and a review of the movie “Unleaded.”

Scroll to Top
Vertisis Custom Pharmacy

Vertisis Custom Pharmacy

Vertisis is one of the most unique sterile-injectable compounding pharmacies in the United States. Our focus is on going “above and beyond” traditional compounding pharmacies by raising the standards of 503A compounding pharmacies to include exceptional products, unique delivery, advanced education, and an amazing relationship with health care providers with a seamless delivery of care. Vertisis originates from over 20 years of clinical practice in custom compounded pharmaceutical agents and over 100 years of combined compounding pharmacy experience with clinical usage of the latest technologies. We have intimate knowledge of hundreds of thousands of custom compounded pharmaceutical treatments with a team of knowledgeable pharmacists to help answer your questions.

Sign up to receive seminar news and updates!

TransLite LLC

345 Commerce Green Blvd.
Sugar Land, TX 77478

TransLite LLC is a small high tech company comprising dedicated people who design, manufacture and sell medical devices that can help reduce the pain and trauma to patients during venous access and treatment of varicose veins.
Our mission is
• To design innovative medical products that help mankind
• Produce highest quality products at affordable prices
• Provide excellent service and support to our customers
We are accomplishing our mission by providing Veinlites® to healthcare professionals all over the world. Since 1999, over 40,000 medical professionals have come to rely on Veinlite® vein finders for simple and consistent one-stick vein access. If failed IV attempts are a daily occurrence among your team, don’t get frustrated…get Veinlite®!

Phone: (281) 240-3111
Fax: (281) 240-3122

With Veinlite® products, you can locate and access veins within seconds – even in the most difficult patients whether due to their age, weight, or skin tone.
Please visit or contact us for more information at or 281-240-3111.

McGuff Family of Companies

Legacy Corporate Contributor
2921 W. MacArthur Blvd., Suite 142
Santa Ana, CA 92704

McGuff Company Inc. is a wholesale distributor of over 5,000 competitively prices pharmaceuticals, IV related products, physician office & exam room supplies and an extensive oral nutritional line to support your patient’s treatments. Our experienced customer service staff are experts at finding hard-to-find products. We maintain close relations with both large and small manufacturers of quality products to assure we will meet all of your needs. Competitive prices for over 35 years!

Verified-Accredited Wholesale Distributor (VAWD)
Phone (800) 854-7220 Toll Free
Fax (714) 540-5614 Toll Free Fax

McGuff Compounding Pharmacy Services specialty pharmacy compounding all dosage forms – preservative-free injections, amino acids, natural hormones and custom formulations all at competitive prices. Injectables are tested for particulates, sterility and endotoxins.

Accredited by the Pharmacy Compounding Accreditation Board (PCAB) &
Independently certified as ISO 9001-2008
Phone (877) 444-1133 Toll Free
Fax (877) 444-1155 Toll Free Fax

P.O. Box 308
Ada, MI 49301-0308
Toll-Free: (844) 733-7847 is committed to helping medical providers and practices overcome the challenges of acquiring the very best custom and non-custom medications. By contracting with multiple FDA-Registered Outsourcing Facilities (503B pharmacies), our goal is to be your source, resource, and solution for the highest quality medications at the most competitive prices.

About partners with 503B pharmacies that specialize in manufacturing medications for IV Nutritional Therapy, Hormone Replacement Therapy & Weight Loss. Our pharmacy partners are held to the highest quality standards by the FDA and comply with USP 795, 797 & cGMP guidelines. For a complete list of the medications we offer, as well as pricing, please contact us at: or 844-73DRUGS

Doctor’s Data, Inc.

3755 lllinois Avenue.
St. Charles, IL 60174 – 2420 USA
US and Canada (800) 323-2784

Doctor’s Data, Inc. has provided innovative specialty testing to healthcare practitioners around the world from our advanced, CLIA-licensed clinical laboratory since 1972. Choose DDI to help you assess and treat heavy metal burden, nutritional deficiencies, gastrointestinal function, hormone and HPA/adrenal function status, cardiovascular risk, liver and metabolic abnormalities, and more.

Simply O3

We help you get started with ozone therapy in your clinic – Grow your income and improve patient outcomes.  Download the DEFINITIVE Guide to Getting Started with Ozone Therapy by going to  Full training and support available  Equipment has a 6 month money back guarantee and is easy to use.  Go download your FREE guide to getting started now at

Merit Pharmaceutical

2611 N. San Fernando Road
Los Angeles, CA 90065
Phone (800) 421-9657 Toll Free US & Canada
Fax (323) 227-4833

Offering IV infusion from Merit? Getting your med/surg/pharma from us? Your colleagues are and they have higher profits. Merit supplies Anti Aging/Aesthetic/Integrative practitioners better prices on the products you use. Call us and learn why successful clinics partner with Merit. IV Therapy Nutrition/Hydration, Weight Loss, Hormones, IV solutions, PRP products, exam/surgical supplies and more. Merit offers pharmaceuticals (2, 3, 3N, 4), and related medical products. or (800) 69-MERIT

Perfect Balance

Perfect Balance, Inc. is providing new hope for cancer victims. We have a proprietary formula which destroys the enzymatic protection of cancer cells and greatly increases NK cell activity. By inhibiting the production of Nagalase the cancer cell can no longer stop the immune system  from doing its job. Innate GC Maf resumes and rapid tumor breakdown is evident. Salicinium enhances NK cell activity and has been shown to kill
both Circulating Tumor Cells and Cancer Stem Cells.

Perfect Balance, Inc. has been in business for more than 25 years and has spent most of that time working in the field of cancer

AMARC Enterprises / POLY-MVA

Contributor, Sponsor and Supporter
San Diego, CA 92021
Phone (866) 765-9682 Toll Free or (619) 447-6500
Fax (619) 447-6501

AMARC Enterprises and Poly-MVA endeavor to treat people honestly and with integrity, and to promote healthy living through our search for the highest quality products. We seek to improve the health and quality of life through practitioners and patients in integrative and regenerative medicine. We know that through smart and targeted therapies with efficacious products people can live fuller, longer and happier lives. Since 2001, AMARC and PolyMVA have been providing quality, FDA compliant products that have helped thousands of people achieve better health.

Lipoic Acid Mineral Complex is the key component that makes Poly-MVA a uniquely-formulated supplement, containing a proprietary blend of the mineral palladium bonded to alpha-lipoic acid, Vitamins B1, B2 and B12, formyl-methionine, N-acetyl cysteine, plus trace amounts of molybdenum, rhodium, and ruthenium. Poly-MVA assists in boosting immune response by targeting key pathways with very specific nutrients and supports cellular metabolism. What makes Poly-MVA unique is the proprietary manufacturing process by which the mineral palladium is sequestered to lipoic acid and thiamin. No other company produces a product similar to Poly-MVA because of the preparation and bonding process through which LAMC is manufactured. The proprietary formulation of LAMC with other vitamins, minerals, and amino acids provides considerable targeted protection and mitochondrial support, helping to enable optimum functioning of multiple essential body systems.

Send in a test question for extra credit. We may add it to future exams!

Sorry. You must be logged in to view this form.